Form 8-K - Current report:
SEC Accession No. 0001213900-15-009144
Filing Date
2015-11-27
Accepted
2015-11-27 16:33:29
Documents
5
Period of Report
2015-11-20
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT f8k112015_actiniumpharma.htm 8-K 16898
2 SECOND AMENDMENT TO THE AMENDED AND RESTATED BYLAWS, AS AMENDED f8k112015ex3ii_actinium.htm EX-3.2 4340
3 PRESS RELEASE f8k112015ex99i_actinium.htm EX-99.1 17838
4 PRESS RELEASE f8k112015ex99ii_actinium.htm EX-99.2 12783
5 GRAPHIC image_002.jpg GRAPHIC 6625
  Complete submission text file 0001213900-15-009144.txt   62391
Mailing Address 546 5TH AVENUE, 14TH FLOOR NEW YORK NY 10036
Business Address 546 5TH AVENUE, 14TH FLOOR NEW YORK NY 10036 212-300-2131
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 151258234
SIC: 2834 Pharmaceutical Preparations